3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: An antagonist with high affinity and selectivity for the human dopamine D4 receptor

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 1941-1942

  Kulagowski, Janusz J ^a   Broughton, Howard B ^a   Curtis, Neil R ^a   Mawer, Ian M ^a   Ridgill, Mark P ^a   Baker, Raymond ^a   Emms, Frances ^a   Freedman, Stephen B ^a   Marwood, Rosemarie ^a   Patel, Shil ^a   Patel, Smita ^a   Ragan, C Ian ^a   Leeson, Paul D ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GRAMINE; HALOPERIDOL; INDOLE DERIVATIVE; L 741626; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN CELL; NEGATIVE SYNDROME; NONHUMAN; RECEPTOR AFFINITY; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; CELL LINE; DOPAMINE ANTAGONISTS; HUMANS; PYRIDINES; PYRROLES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4;

EID: 0012409009     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9600712     Document Type: Article

References (23)

1. Devis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in Schizophrenia: A Review and Reconceptualization. Am. J. Psychiatry 1991, 148, 1474-1486.
2. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. Science 1976, 192, 481-483.
3. Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133-152.
4. Reynolds, G. P. Developments in the Drug Treatment of Schizophrenia. Trends Pharm. Sci. 1992, 13, 116-121.
5. Fitton, A.; Heel, R. C. Clozapine. A Review of its Pharmacological Properties, and Therapeutic Use in Schizophrenia. Drugs 1990, 40, 722-747.
6. Krupp, P.; Barnes, P. Clozapine-Associated Agranulocytosis: Risk and Aetiology. Br. J. Psychiatry 1992, 160 (suppl. 17), 38-41.
7. Moore, N. A.; Tupper, D. E.; Hotten, T. M. Olanzapine. Drugs Future 1994, 19, 114-117.
8. i Values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
9. 2 Ratio Hypothesis. Curr. Med. Chem. 1994, 1, 50-60.
10. (a) Howard, H. R.; Prakash, C.; Seeger, T. F. Ziprasidone Hydrochloride. Drugs Future 1994, 19, 560-563.
11. (b) Sánchez, C.; Arnt, J.; Dragsted, N.; Hyttel, J.; Lembøl, H. L.; Meier, E.; Perregaard, J.; Skarsfeldt, T. Neurochemical and In Vivo Pharmacological Profile of Sertindole, a Limbic-Selective Neuroleptic Compound. Drug Dev. Res. 1991, 22, 239-250.
12. 2 Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873). J. Med. Chem. 1995, 38, 1119-1131.
13. Tricklebank, M. D.; Bristow, L. J.; Hutson, P. H. Alternative Approaches to the Discovery of Novel Antipsychotic Agents. Prog. Drug Res. 1992, 38, 299-336.
14. (a) Sibley, D. R.; Monsma, F. J., Jr. Molecular Biology of Dopamine Receptors. Trends Pharmacol. Sci. 1992, 13, 61-69.
15. (b) Grandy, D. K.; Civelli, O. G-Protein-Coupled Receptors: The New Dopamine Receptor Subtypes. Curr. Opin. Neurobiol. 1992, 2, 275-281.
16. 4 Receptor With High Affinity for the Antipsychotic Clozapine. Nature 1991, 350, 610-615.
17. 4. Neuropsychopharmacology 1992, 7, 261-284.
18. 4 Receptors in Drug-Treated Schizophrenia. Eur. J. Pharmacol. 1995, 281, R5-R6.
19. 4 Receptors Elevated in Schizophrenia. Nature 1993, 365, 441-445.
20. TOPOSIM implemented by Kearsley, S. K., Molecular Systems, Merck and Co., Rahway, NJ.
21. 3 Dopamine Receptor. J. Pharmacol. Exp. Ther. 1994, 268, 417-426.
22. 4 Dopamine Receptors in HEK293 Cells. J. Recep. Sig. Trans. Res. 1995, 15, 267-281.
23. Williamson, W. R. N. Synthesis of 3-(2-Aminopropyl)-1H-pyrrolo-[2,3-b]pyridine. J. Chem. Soc. 1962, 2833.